An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of intetumumab when given in combination
with docetaxel and prednisone to participants with metastatic (spread of cancer cells from
one part of the body to another) hormone-refractory (not responding to treatment) prostate
cancer (abnormal tissue that grows and spreads in the body until it kills).